The Comparative Efficacy of Cimetidine and Ranitidine in Controlling Gastric

Total Page:16

File Type:pdf, Size:1020Kb

The Comparative Efficacy of Cimetidine and Ranitidine in Controlling Gastric 287 The comparative efficacy of cimeti- dine and ranitidine in controlling gastric pH in critically ill Stewart Ross Reid MD, Charles Dugald Bayliff PHARMD patients The comparative efficacy of intravenous cimetidine and The use of cimetidine, a histamine-2 (H2) receptor ranitidine in controlling gastric pH in 100 intensive care antagonist, and antacids to increase gastric acid pH unit patients was assessed in a double blind, prospective, and reduce the risk of stress ulceration is well randomized study. The total number of gastric pH deter- documented.l-3 While some studies have shown minations and the number of pH determinations with pH antacids to be superior to cimetidine 4-5 others have less than five were recorded. Patients received either stated that cimetidine is equally efficacious. 1'3 cimetidine or ranitidine via continuous infusion, with Proponents of the use of cimetidine have cited dosage adjustments for patients with renal insufficiency. equal efficacy, convenience (versus hourly titration Antacids were administered each time the gastric pH was of antacid) and reduced incidence of adverse effects less than five. There was no difference overall in the when compared to high dose antacids as the reasons number of patients who had at least one gastric pH for its widespread use. L3 determination < pH 5. There was however, a larger pro- However, cimetidine is a less than ideal agent in portion of patients with >-10, >-15. >--20 and >-25 per the critically ill, especially because of central cent of gastric pH determination < pH 5 in the cimetidine nervous system toxicity and the potential for drug group than in the ranitidine group. This difference was interactions. 6-s Ranitidine, a recently released H2 statistically significant for >25 per cent. The drugs were receptor antagonist, may offer an advantage over well tolerated. Ranitidine was as effective as cimetidine cimetidine since it does not result in the same degree and possibly more so in controlling gastric pH. of neurological toxicity nor interfere with drug metabolism in therapeutic doses. 9 Ranitidine may also be effective when cimetidine has failed, j~ Based on these potential advantages, it seemed appropriate to compare intravenous cimetidine and intravenous ranitidine in the control of gastric pH. Key words GASTROINTESTINAL TRACT: gastric pH, cimetidine, Methods ranitidine; HISTAMINE-2 RECEPTOR ANTAGONISTS: From July 13, 1983 to January 7, 1984,100 patients cimetidine, ranitidine. admitted to the Surgical Intensive Care Unit (SICU) who underwent randomization within 12 hours of From the Departments of Anaesthesia and Pharmacy, admission to the unit were entered into the study, University of Toronto, Sunnybrook Medic',d Centre, providing no exclusion criteria were present. Speci- Toronto, Ontario. fic exclusion criteria were: known hypersensitivity Address correspondence to: Dr. S. R. Reid, Depart- to cimetidine or ranitidine; previous upper gastroin- ment of Anaesthesia, Sunnybrook Medical Centre, 2075 testinal surgery; previous history/evidence of pre- Bayview Avenue, Toronto, Ontario, Canada, M4N 3M5. existing peptic ulcer disease; severe liver disease; Supported in part by Glaxo Canada Limited. haemorrhagic diathesis; moderate pre-existing re- CAN ANAESTH SOC J 1986 / 33:3 / pp287-93 288 CANADIAN ANAESTHETISTS' SOCIETY JOURNAL TABLE 1 Drug doses related to renal function continuous EKG monitoring and an assessment of the Glascow Coma Scale daily. The patients were Creatinine clearance Cimetidine dose Ranitidine dose continued in the study until one of the following > 1 ml/sec 1200 mg/day events occurred: 0.2- I. 0 ml/sec 900 mg/day 1 The patient received a full seven days of therapy. <0.2 ml/sec 600 mg/day 2 The patient was started on oral or nasogastric >0.2 rob'see 300 rag/day feedings. -<0.2 ml/sec 150 mg/day 3 The patient experienced a major gastrointestinal bleed defined as appreciable or continued appear- nal insufficiency (serum creatinine -> 260 ance of blood either fresh or altered blood in the mmol-L-l); prior use of an H2 receptor antagonist nasogastric secretions or melena stools asso- or antacids within 24 hours; age less than 12 years; ciated with a drop in haemoglobin of 20 g.L- ~or pregnant or nursing women; previous history of more. pyloric stenosis, oesophageal stricture, oesopha- 4 The patient developed an adverse effect of geal ring, scleroderma, hiatus hernia or atrophic significant magnitude to preclude continuation of gastritis; a body weight < 40 kg or > 90 kg. the study. Informed consent was obtained from the patient or 5 The patient expired. next of kin. The protocol was reviewed and ac- The number of pH readings < pH 5 and total cepted by the University and Hospital Research number of pH readings were recorded. Patients and Ethics Committees. were deemed eligible for analysis only if they Patients were randomly allocated, by selecting completed 36 hours in the study and had at least nine the next consecutive number box, to receive either gastric acid determinations. Differences between cimetidine 300 mg intravenously over 20 minutes means were analyzed by an unpaired t-test. Differ- followed by a continuous intravenous infusion of ences between proportions were measured by Chi 50 mg per hour (1200 mg daily) or ranitidine 50 mg square analysis. The level of p < 0.05 was con- intravenously over 20 minutes followed by a con- sidered significant. tinuous infusion of 12.5mg per hour (300mg daily). Syringes of the drug were prepared and Results boxes containing these drug kits (for first 24-hour Of the original 100 patients entered in the study 71 period) were stored in the SICU. These kits were (38 of the cimetidine group and 33 of the ranitidine prepared by the Department of Pharmacy with group) were included in the final analysis. The 17 neither the SICU staff nor the patient having patients not included for analysis in the ranitidine knowledge of which drug the kit contained. The group were excluded for the following reasons: nine Pharmacy Department was responsible for supply- improved and were transferred from the SICU in ing subsequent solutions of appropriate drug and less than 36 hours, three died within 36 hours, two any necessary dosage alterations. Patients with mild were started on tube feedings, two were excluded pre-existing renal insufficiency or who developed for an inadequate number of samples and one was renal insufficiency while on study received reduced excluded because of body weight < 40 kg. The 12 doses as indicated in Table I. patients in the cimetidine group not included for A nasogastric tube was inserted and gastric pH analysis were excluded for the following reasons: was measured every four hours using a commer- seven improved and were transferred in less than 36 cially available pH sensitive tape (Colourphast| hours, two died within 36 hours, one was excluded commencing at time 0. Thirty ml of antacid (Gelusil for an inadequate number of samples, one was Extra Strength| was administered via the nasogas- excluded because of body weight > 90 kg and one tric tube if the pH was less than five. Routine blood because of the drug infusion being inadvertently work including serum electrolytes, BUN and creati- turned off for a period of 12 hours. The demo- nine were measured daily. Liver function tests were graphic data are shown in Table II. The two groups done on the day of admission and the day of were comparable with respect to age, sex and hours discharge. Thyroid function tests were done on in the study. admission and one week later. All patients had When patients who failed to have gastric pH Reid and Bayliff: H 2 ANTAGONISTS AND CONTROL OF GASTRIC PH 289 TABLE II Demographicdata TABLE IV Outcomeof patients Cimetidine Ranitidine Cimetidine Ranitidine group group (n = 38) (n = 33) (n = 38) (n = 33) Mortality 7/38 (18.4%) 6/33 (18.2%) Age(years) 39.1-19.4 41.3• Evidenceof bleed 1/38 2/33 Sex (M/F) 24/14 19/14 Length of study time (hours) 81.8 -+ 36.1 91.7-+ 82.0 Primary diagnosis Vascular 3 6 group had microscopic bleeding. This difference Craniofacial surgery 4 4 between groups was not statistically significant. Trauma 11 8 After excluding the first aspirate obtained at time Closed head injury --- trauma 11 7 0, 27 of the 38 patients (71.1 per cent) receiving Neurosurgical/spinalcord trauma 5 5 Acute respiratory failure 1 1 eimetidine had a pH <5 on at least one occasion Sepsis 0 1 while 22 of 33 patients (66.7 per cent) receiving Other (myocardial infarction, 3 0 ranitidine had a pH <5 on at least one occasion seizures, CVA) (p = NS). There were a number of patients in both groups who were completely controlled with these agents. Subsequent analysis of the data and division controlled were placed in risk groups one through of the patients into groups based on the percentage five depending on the number of risk factors of gastric pH determinations of <5 revealed the present, there was no significant difference be- information summarized in the Figure. Poor control tween the groups (Table III) even though there were five patients in the cimetidine group with five risk factors but only one in the ranitidine 60 [•CimeUdlne group with five risk factors. There were no pa- tients who had more than five of the seven risk [] Ranltldine factors. The seven risk factors for stress ulcer- ation included sepsis, respiratory failure, major 50 operative procedures, renal failure, hypotension, -r multiple trauma, head injury and spinal cord injury. r Data were not specifically analyzed within each of 40 the risk groups because of the small numbers in each group. There was no statistical correlation between the number of risk factors and the inability to 30 control gastric pH (r = -0.038).
Recommended publications
  • ZANTAC® 150 (Ranitidine Hydrochloride) Tablets, USP
    PRESCRIBING INFORMATION ZANTAC® 150 (ranitidine hydrochloride) Tablets, USP ZANTAC® 300 (ranitidine hydrochloride) Tablets, USP ZANTAC® 25 (ranitidine hydrochloride effervescent) ® EFFERdose Tablets ® ZANTAC (ranitidine hydrochloride) Syrup, USP DESCRIPTION The active ingredient in ZANTAC 150 Tablets, ZANTAC 300 Tablets, ZANTAC 25 EFFERdose Tablets, and ZANTAC Syrup is ranitidine hydrochloride (HCl), USP, a histamine H2-receptor antagonist. Chemically it is N[2-[[[5-[(dimethylamino)methyl]-2­ furanyl]methyl]thio]ethyl]-N′-methyl-2-nitro-1,1-ethenediamine, HCl. It has the following structure: The empirical formula is C13H22N4O3S•HCl, representing a molecular weight of 350.87. Ranitidine HCl is a white to pale yellow, granular substance that is soluble in water. It has a slightly bitter taste and sulfurlike odor. Each ZANTAC 150 Tablet for oral administration contains 168 mg of ranitidine HCl equivalent to 150 mg of ranitidine. Each tablet also contains the inactive ingredients FD&C Yellow No. 6 Aluminum Lake, hypromellose, magnesium stearate, microcrystalline cellulose, titanium dioxide, triacetin, and yellow iron oxide. Each ZANTAC 300 Tablet for oral administration contains 336 mg of ranitidine HCl equivalent to 300 mg of ranitidine. Each tablet also contains the inactive ingredients croscarmellose sodium, D&C Yellow No. 10 Aluminum Lake, hypromellose, magnesium stearate, microcrystalline cellulose, titanium dioxide, and triacetin. 1 ZANTAC 25 EFFERdose Tablets for oral administration is an effervescent formulation of ranitidine that must be dissolved in water before use. Each individual tablet contains 28 mg of ranitidine HCl equivalent to 25 mg of ranitidine and the following inactive ingredients: aspartame, monosodium citrate anhydrous, povidone, and sodium bicarbonate. Each tablet also contains sodium benzoate.
    [Show full text]
  • 2D6 Substrates 2D6 Inhibitors 2D6 Inducers
    Physician Guidelines: Drugs Metabolized by Cytochrome P450’s 1 2D6 Substrates Acetaminophen Captopril Dextroamphetamine Fluphenazine Methoxyphenamine Paroxetine Tacrine Ajmaline Carteolol Dextromethorphan Fluvoxamine Metoclopramide Perhexiline Tamoxifen Alprenolol Carvedilol Diazinon Galantamine Metoprolol Perphenazine Tamsulosin Amiflamine Cevimeline Dihydrocodeine Guanoxan Mexiletine Phenacetin Thioridazine Amitriptyline Chloropromazine Diltiazem Haloperidol Mianserin Phenformin Timolol Amphetamine Chlorpheniramine Diprafenone Hydrocodone Minaprine Procainamide Tolterodine Amprenavir Chlorpyrifos Dolasetron Ibogaine Mirtazapine Promethazine Tradodone Aprindine Cinnarizine Donepezil Iloperidone Nefazodone Propafenone Tramadol Aripiprazole Citalopram Doxepin Imipramine Nifedipine Propranolol Trimipramine Atomoxetine Clomipramine Encainide Indoramin Nisoldipine Quanoxan Tropisetron Benztropine Clozapine Ethylmorphine Lidocaine Norcodeine Quetiapine Venlafaxine Bisoprolol Codeine Ezlopitant Loratidine Nortriptyline Ranitidine Verapamil Brofaramine Debrisoquine Flecainide Maprotline olanzapine Remoxipride Zotepine Bufuralol Delavirdine Flunarizine Mequitazine Ondansetron Risperidone Zuclopenthixol Bunitrolol Desipramine Fluoxetine Methadone Oxycodone Sertraline Butylamphetamine Dexfenfluramine Fluperlapine Methamphetamine Parathion Sparteine 2D6 Inhibitors Ajmaline Chlorpromazine Diphenhydramine Indinavir Mibefradil Pimozide Terfenadine Amiodarone Cimetidine Doxorubicin Lasoprazole Moclobemide Quinidine Thioridazine Amitriptyline Cisapride
    [Show full text]
  • Receptor Antagonist (H RA) Shortages | May 25, 2020 2 2 2 GERD4,5 • Take This Opportunity to Determine If Continued Treatment Is Necessary
    H2-receptor antagonist (H2RA) Shortages Background . 2 H2RA Alternatives . 2 Therapeutic Alternatives . 2 Adults . 2 GERD . 3 PUD . 3 Pediatrics . 3 GERD . 3 PUD . 4 Tables Table 1: Health Canada–Approved Indications of H2RAs . 2 Table 2: Oral Adult Doses of H2RAs and PPIs for GERD . 4 Table 3: Oral Adult Doses of H2RAs and PPIs for PUD . 5 Table 4: Oral Pediatric Doses of H2RAs and PPIs for GERD . 6 Table 5: Oral Pediatric Doses of H2RAs and PPIs for PUD . 7 References . 8 H2-receptor antagonist (H2RA) Shortages | May 25, 2020 1 H2-receptor antagonist (H2RA) Shortages BACKGROUND Health Canada recalls1 and manufacturer supply disruptions may be causing shortages of commonly used acid-reducing medications called histamine H2-receptor antagonists (H2RAs) . H2RAs include cimetidine, famotidine, nizatidine and ranitidine . 2 There are several Health Canada–approved indications of H2RAs (see Table 1); this document addresses the most common: gastroesophageal reflux disease (GERD) and peptic ulcer disease (PUD) . 2 TABLE 1: HEALTH CANADA–APPROVED INDICATIONS OF H2RAs H -Receptor Antagonists (H RAs) Health Canada–Approved Indications 2 2 Cimetidine Famotidine Nizatidine Ranitidine Duodenal ulcer, treatment ü ü ü ü Duodenal ulcer, prophylaxis — ü ü ü Benign gastric ulcer, treatment ü ü ü ü Gastric ulcer, prophylaxis — — — ü GERD, treatment ü ü ü ü GERD, maintenance of remission — ü — — Gastric hypersecretion,* treatment ü ü — ü Self-medication of acid indigestion, treatment and prophylaxis — ü† — ü† Acid aspiration syndrome, prophylaxis — — — ü Hemorrhage from stress ulceration or recurrent bleeding, — — — ü prophylaxis ü = Health Canada–approved indication; GERD = gastroesophageal reflux disease *For example, Zollinger-Ellison syndrome .
    [Show full text]
  • Stems for Nonproprietary Drug Names
    USAN STEM LIST STEM DEFINITION EXAMPLES -abine (see -arabine, -citabine) -ac anti-inflammatory agents (acetic acid derivatives) bromfenac dexpemedolac -acetam (see -racetam) -adol or analgesics (mixed opiate receptor agonists/ tazadolene -adol- antagonists) spiradolene levonantradol -adox antibacterials (quinoline dioxide derivatives) carbadox -afenone antiarrhythmics (propafenone derivatives) alprafenone diprafenonex -afil PDE5 inhibitors tadalafil -aj- antiarrhythmics (ajmaline derivatives) lorajmine -aldrate antacid aluminum salts magaldrate -algron alpha1 - and alpha2 - adrenoreceptor agonists dabuzalgron -alol combined alpha and beta blockers labetalol medroxalol -amidis antimyloidotics tafamidis -amivir (see -vir) -ampa ionotropic non-NMDA glutamate receptors (AMPA and/or KA receptors) subgroup: -ampanel antagonists becampanel -ampator modulators forampator -anib angiogenesis inhibitors pegaptanib cediranib 1 subgroup: -siranib siRNA bevasiranib -andr- androgens nandrolone -anserin serotonin 5-HT2 receptor antagonists altanserin tropanserin adatanserin -antel anthelmintics (undefined group) carbantel subgroup: -quantel 2-deoxoparaherquamide A derivatives derquantel -antrone antineoplastics; anthraquinone derivatives pixantrone -apsel P-selectin antagonists torapsel -arabine antineoplastics (arabinofuranosyl derivatives) fazarabine fludarabine aril-, -aril, -aril- antiviral (arildone derivatives) pleconaril arildone fosarilate -arit antirheumatics (lobenzarit type) lobenzarit clobuzarit -arol anticoagulants (dicumarol type) dicumarol
    [Show full text]
  • IHS National Pharmacy & Therapeutics Committee National
    IHS National Pharmacy & Therapeutics Committee National Core Formulary; Last Updated: 09/23/2021 **Note: Medications in GREY indicate removed items.** Generic Medication Name Pharmacological Category (up-to-date) Formulary Brief (if Notes / Similar NCF Active? available) Miscellaneous Medications Acetaminophen Analgesic, Miscellaneous Yes Albuterol nebulized solution Beta2 Agonist Yes Albuterol, metered dose inhaler Beta2 Agonist NPTC Meeting Update *Any product* Yes (MDI) (Nov 2017) Alendronate Bisphosphonate Derivative Osteoporosis (2016) Yes Allopurinol Antigout Agent; Xanthine Oxidase Inhibitor Gout (2016) Yes Alogliptin Antidiabetic Agent, Dipeptidyl Peptidase 4 (DPP-4) Inhibitor DPP-IV Inhibitors (2019) Yes Anastrozole Antineoplastic Agent, Aromatase Inhibitor Yes Aspirin Antiplatelet Agent; Nonsteroidal Anti-Inflammatory Drug; Salicylate Yes Azithromycin Antibiotic, Macrolide STIs - PART 1 (2021) Yes Calcium Electrolyte supplement *Any formulation* Yes Carbidopa-Levodopa (immediate Anti-Parkinson Agent; Decarboxylase Inhibitor-Dopamine Precursor Parkinson's Disease Yes release) (2019) Clindamycin, topical ===REMOVED from NCF=== (See Benzoyl Peroxide AND Removed January No Clindamycin, topical combination) 2020 Corticosteroid, intranasal Intranasal Corticosteroid *Any product* Yes Cyanocobalamin (Vitamin B12), Vitamin, Water Soluble Hematologic Supplements Yes oral (2016) Printed on 09/25/2021 Page 1 of 18 National Core Formulary; Last Updated: 09/23/2021 Generic Medication Name Pharmacological Category (up-to-date) Formulary Brief
    [Show full text]
  • Wednesday, July 10, 2019 4:00Pm
    Wednesday, July 10, 2019 4:00pm Oklahoma Health Care Authority 4345 N. Lincoln Blvd. Oklahoma City, OK 73105 The University of Oklahoma Health Sciences Center COLLEGE OF PHARMACY PHARMACY MANAGEMENT CONSULTANTS MEMORANDUM TO: Drug Utilization Review (DUR) Board Members FROM: Melissa Abbott, Pharm.D. SUBJECT: Packet Contents for DUR Board Meeting – July 10, 2019 DATE: July 3, 2019 NOTE: The DUR Board will meet at 4:00pm. The meeting will be held at 4345 N. Lincoln Blvd. Enclosed are the following items related to the July meeting. Material is arranged in order of the agenda. Call to Order Public Comment Forum Action Item – Approval of DUR Board Meeting Minutes – Appendix A Update on Medication Coverage Authorization Unit/SoonerPsych Program Update – Appendix B Action Item – Vote to Prior Authorize Jornay PM™ [Methylphenidate Extended-Release (ER) Capsule], Evekeo ODT™ [Amphetamine Orally Disintegrating Tablet (ODT)], Adhansia XR™ (Methylphenidate ER Capsule), and Sunosi™ (Solriamfetol Tablet) – Appendix C Action Item – Vote to Prior Authorize Balversa™ (Erdafitinib) – Appendix D Action Item – Vote to Prior Authorize Annovera™ (Segesterone Acetate/Ethinyl Estradiol Vaginal System), Bijuva™ (Estradiol/Progesterone Capsule), Cequa™ (Cyclosporine 0.09% Ophthalmic Solution), Corlanor® (Ivabradine Oral Solution), Crotan™ (Crotamiton 10% Lotion), Gloperba® (Colchicine Oral Solution), Glycate® (Glycopyrrolate Tablet), Khapzory™ (Levoleucovorin Injection), Qmiiz™ ODT [Meloxicam Orally Disintegrating Tablet (ODT)], Seconal Sodium™ (Secobarbital
    [Show full text]
  • CLINICAL REVIEW(S) Clinical Review Michael C
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 210655Orig1s000 CLINICAL REVIEW(S) Clinical Review Michael C. Davis, MD, PhD and Qi Chen, MD, MPH (Safety Review) NDA 210655 Perseris (RBP-7000 risperidone-ATRIGEL) CLINICAL REVIEW Application Type Initial 505(b)(2) New Drug Application (NDA) Application Number(s) 210655 Priority or Standard Standard Submit Date(s) September 28, 2017 Received Date(s) September 28, 2017 PDUFA Goal Date July 28, 2018 Division/Office Division of Psychiatry Products/Office of Drug Evaluation I Reviewer Name(s) Michael C. Davis, MD, PhD; Qi Chen, MD, MPH (Safety Review) Review Completion Date June 22, 2018 Established/Proper Name RBP-7000 (risperidone-ATRIGEL) (Proposed) Trade Name Perseris Applicant Indivior Dosage Form(s) Injectable Suspension Applicant Proposed Dosing 90 mg or 120 mg subcutaneous injection monthly Regimen(s) Applicant Proposed Schizophrenia/Adults Indication(s)/Population(s) Recommendation on Approve Regulatory Action Recommended N/A Indication(s)/Population(s) (if applicable) CDER Clinical Review Template 1 Version date: September 6, 2017 for all NDAs and BLAs Reference ID: 4288016 Clinical Review Michael C. Davis, MD, PhD and Qi Chen, MD, MPH (Safety Review) NDA 210655 Perseris (RBP-7000 risperidone-ATRIGEL) Table of Contents Glossary ........................................................................................................................................... 9 1. Executive Summary ..............................................................................................................
    [Show full text]
  • Wednesday, June 12, 2019 4:00Pm
    Wednesday, June 12, 2019 4:00pm Oklahoma Health Care Authority 4345 N. Lincoln Blvd. Oklahoma City, OK 73105 The University of Oklahoma Health Sciences Center COLLEGE OF PHARMACY PHARMACY MANAGEMENT CONSULTANTS MEMORANDUM TO: Drug Utilization Review (DUR) Board Members FROM: Melissa Abbott, Pharm.D. SUBJECT: Packet Contents for DUR Board Meeting – June 12, 2019 DATE: June 5, 2019 Note: The DUR Board will meet at 4:00pm. The meeting will be held at 4345 N. Lincoln Blvd. Enclosed are the following items related to the June meeting. Material is arranged in order of the agenda. Call to Order Public Comment Forum Action Item – Approval of DUR Board Meeting Minutes – Appendix A Update on Medication Coverage Authorization Unit/Use of Angiotensin Converting Enzyme Inhibitor (ACEI)/ Angiotensin Receptor Blocker (ARB) Therapy in Patients with Diabetes and Hypertension (HTN) Mailing Update – Appendix B Action Item – Vote to Prior Authorize Aldurazyme® (Laronidase) and Naglazyme® (Galsulfase) – Appendix C Action Item – Vote to Prior Authorize Plenvu® [Polyethylene Glycol (PEG)-3350/Sodium Ascorbate/Sodium Sulfate/Ascorbic Acid/Sodium Chloride/Potassium Chloride] – Appendix D Action Item – Vote to Prior Authorize Consensi® (Amlodipine/Celecoxib) and Kapspargo™ Sprinkle [Metoprolol Succinate Extended-Release (ER)] – Appendix E Action Item – Vote to Update the Prior Authorization Criteria For H.P. Acthar® Gel (Repository Corticotropin Injection) – Appendix F Action Item – Vote to Prior Authorize Fulphila® (Pegfilgrastim-jmdb), Nivestym™ (Filgrastim-aafi),
    [Show full text]
  • Effervescent H2 Blocker Formulation
    Europaisches Patentamt European Patent Office © Publication number: 0 492 247 A1 Office europeen des brevets EUROPEAN PATENT APPLICATION © Application number: 91121064.9 © int. CIA A61K 31/34, A61K 9/00 @ Date of filing: 09.12.91 ® Priority: 21.12.90 US 633230 @ Inventor: Paulos, Manley A. 15626 Cold Springs Court @ Date of publication of application: Indiana 01.07.92 Bulletin 92/27 Granger, 46530(US) © Designated Contracting States: AT BE CH DE DK ES FR GB GR IT LI LU NL SE © Representative: Danner, Klaus, Dr. et al c/o Bayer AG Konzernverwaltung RP © Applicant: MILES INC. 1127 Myrtle Street Patentabteilung ElkhartJN 4651 5(US) W-5090 Leverkusen 1 Bayerwerk(DE) (§v Effervescent H2 blocker formulation. © An aqueous solution of H2 Blocker and an effervescent delivery system. Immediate and continuous relief is provided for from about 1 to about 3 hours, even when the administered composition contains less than about 25 percent of the dosage of H2 Blocker prescribed for active duodenal ulcer. 7.0 r 0,3mg/kg+0,0mEq 7.0 0,3 mg/kg + 32mEq 0,0mg/kg+0,0mEq 0,0mg/kg +0,0mE q 6.0 6,0 5,0 5,0 Xa. *4.0 :4.0 ^3.0 :3,0 1^2,0 h is 2,0 1.0 h 1.0 ■ 0.0 _i i ■ ■ 0.0 CM -60 0 60 120 180 240 -60 0 60 120 180 240 Time After Dosing (Minutes) CM Time After Dosing (Minutes) Oi FIG.1Q FIG.Id Rank Xerox (UK) Business Services EP 0 492 247 A1 Background of the Invention Histamine H2 receptor blocking agents (referred to herein as H2 Blockers) are a class of drugs which act as antagonists of the histamine H2 receptor.
    [Show full text]
  • Appendix 1 BNF Codes of Drugs Lists Used to Define Exposure Groups
    Appendix 1 BNF Codes of drugs lists used to define exposure groups. Anticholinergic antipsychotics d411. Chlorpromazine d412. Chlorpromazine d413. Chlorpromazine d414. Chlorpromazine d415. Chlorpromazine d41a. Chlorpromazine d41b. Chlorpromazine d41c. Chlorpromazine d41d. Chlorpromazine d4b1. Perphenazine d4e1. PROMAZINE d4ex. PROMAZINE d4g.. Thioridazine d4g1. Thioridazine d4g2. Thioridazine d4g3. Thioridazine d4g5. Thioridazine d4g7. Thioridazine d4gp. Thioridazine d4gt. Thioridazine d4gu. Thioridazine d4gv. Thioridazine d4gw. Thioridazine d4gz. Thioridazine d4h.. Trifluoperazine d4h1. Trifluoperazine d4h2. Trifluoperazine d4h3. Trifluoperazine d4h4. Trifluoperazine d4hs. Trifluoperazine d4ht. Trifluoperazine d4hu. Trifluoperazine d4hx. Trifluoperazine d4l2. CLOZAPINE d4r1. OLANZAPINE d4r3. OLANZAPINE d4r7. OLANZAPINE d4s1. QUETIAPINE d4s2. QUETIAPINE d4s3. QUETIAPINE d4s5. QUETIAPINE d4ss. QUETIAPINE d4sx. QUETIAPINE Tricyclic antidepressants d7... d71.. Amitriptyline d711. Amitriptyline d712. Amitriptyline d713. Amitriptyline d719. Amitriptyline d71a. Amitriptyline d71b. Amitriptyline d71c. Amitriptyline d71d. Amitriptyline d71e. Amitriptyline d71f. Amitriptyline d71u. Amitriptyline d71v. Amitriptyline d71w. Amitriptyline d71y. Amitriptyline d71z. Amitriptyline d73.. Clomipramine d731. Clomipramine d732. Clomipramine d733. Clomipramine d736. Clomipramine d73s. Clomipramine d73t. Clomipramine d73u. Clomipramine d73v. Clomipramine d73w. Clomipramine d73z. Clomipramine d75.. DOSULEPIN d751. DOSULEPIN d752. DOSULEPIN d755. DOSULEPIN d756.
    [Show full text]
  • Carvedilol Suppresses Intractable Hiccups
    J Am Board Fam Med: first published as 10.3122/jabfm.19.4.418 on 29 June 2006. Downloaded from BRIEF REPORTS Carvedilol Suppresses Intractable Hiccups Danielle Stueber, MD, and Conrad M. Swartz, PhD, MD Carvedilol (6.25 mg, 4 times daily) relieved 2 years of constant hiccupping, marked tardive dyskinesia, compulsive self-induced vomiting, and feelings of hopelessness and low mood in a 59-year-old African- American man. He previously failed trials of ranitidine, chlorpromazine, promethazine, tegaserod, on- dansetron, metoclopramide, pantoprazole, pyloric injections of botulinum toxin A, and a vagal nerve stimulator. At a 5-month follow-up, improvement was maintained; there had been several instances of rapid relapse on carvedilol discontinuation. (J Am Board Fam Med 2006;19:418–21.) This report describes a case of persistent and in- Case Reports tractable postoperative hiccups of 2 years duration The patient was a 59-year-old African-American that responded to carvedilol after nonresponse to man, admitted to the hospital for nausea, frequent typical therapies. The chronic singultus was one of coffee ground hematemesis, and associated anemia, several concurrent pathologic conditions, including besides unrelenting hiccups. Hiccups began episod- self-induced vomiting, tardive dyskinesia secondary ically 10 years prior. These episodes were initially to metoclopramide use, and depressed mood. relieved by self-induced vomiting and attributed to Although major causes of hiccups are associated diabetic gastroparesis. The patient underwent sev- with gastrointestinal ailments, persistent hiccups eral upper endoscopic examinations, which re- can be induced by tumors, chemotherapy, diabetes, vealed gastric erosions, a 3-cm hiatal hernia, and a uremia, or brain disease.
    [Show full text]
  • Early Effects of Oral Administration of Omeprazole and Roxatidine on Intragastric Ph
    Iida et al. / J Zhejiang Univ-Sci B (Biomed & Biotechnol) 2012 13(1):29-34 29 Journal of Zhejiang University-SCIENCE B (Biomedicine & Biotechnology) ISSN 1673-1581 (Print); ISSN 1862-1783 (Online) www.zju.edu.cn/jzus; www.springerlink.com E-mail: [email protected] Early effects of oral administration of omeprazole and roxatidine on intragastric pH Hiroshi IIDA1, Shingo KATO1, Yusuke SEKINO1, Eiji SAKAI1, Takashi UCHIYAMA1, Hiroki ENDO1, Kunihiro HOSONO1, Yasunari SAKAMOTO1, Koji FUJITA1, Masato YONEDA1, Tomoko KOIDE1, Hirokazu TAKAHASHI1, Chikako TOKORO1, Ayumu GOTO1, Yasunobu ABE1, Noritoshi KOBAYASHI1, Kensuke KUBOTA1, Eiji GOTOH2, Shin MAEDA1, Atsushi NAKAJIMA1, Masahiko INAMORI†‡1,3 (1Gastroenterology Division, Yokohama City University School of Medicine, Yokohama 236-0004, Japan) (2Department of Medical Education, Yokohama City University School of Medicine, Yokohama 236-0004, Japan) (3Office of Postgraduate Medical Education, Yokohama City University Hospital, Yokohama 236-0004, Japan) †E-mail: [email protected] Received Mar. 14, 2011; Revision accepted Aug. 30, 2011; Crosschecked Dec. 2, 2011 Abstract: Objective: The ideal medication for the treatment of acid-related diseases, e.g., peptic ulcers, stress- related gastric bleeding, functional dyspepsia, and gastroesophageal reflux disease, should have a rapid onset of action to promote hemostasis and relieve the symptoms. The aim of our study was to investigate the inhibitory effects on gastric acid secretion of a single oral administration of a proton pump inhibitor, omeprazole 20 mg, and an H2-receptor antagonist, roxatidine 75 mg. Methods: Ten Helicobacter pylori-negative male subjects participated in this randomized, two-way crossover study. Intragastric pH was monitored continuously for 6 h after single oral admini- stration of omeprazole 20 mg and roxatidine 75 mg.
    [Show full text]